AB
AEON BiopharmaClinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.
1 Pulse story
A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
Total RaisedNot disclosed
Last ValuationNot disclosed
Biotech
Sector
Biotech
2013
Founded
2017
Irvine, California
HQ
Cambridge, Massachusetts
Public (AEON)
Status
Public (APMD)
AEON Biopharma investors
No investors on record.
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Data from Value Add Pulse coverage and company research — see the full threads for AEON Biopharma and Apnimed.